Index 1197

Index

(+)-Desmethyl-sibutramine, 1193 1129, 1130, 1131, 1132, 1133, 1134, 1137, 1138, 1139, 1140, 1141, 1142, (+)-Didesmethyl-sibutramine, 1193 1143, 1144, 1145, 1155, 1156, 1160, (+)-N-Desmethylzopiclone, 1055 1161, 1163, 1164, 1165, 1166, 1167, 1169, 1170, 1171, 1172, 1173, 1174, (R)-Oxaprotiline, 1068 1175, 1176, 1177, 1183, 1184, 1185, (R)-Tofisopam, 1064 1187, 1189, 1192 (R)-Zacopride, 1061 Adult cases, 1124, 1125, 1127 (S)-Tofisopam, 1055 Classification, 1092 163090, 1056 Comorbidity, 1110, 1111 2-hydroxyimipramine, 176 Costs, 1112 31264-RP, 1065 Definition, 1091, 1105, 1106, 1107, 1108 3-2,4 dimethoxy benylidene, 429 Diagnosis, 1099, 1127, 1128, 1129, 1130, 1132 597599, 1063 Epidemiology, 1108, 1110 5-HT1A antagonists, 116, 117, 250 Etiology, 1095, 1114 5-HT2A antagonists, 117, 493, 553 Environment, 1095, 1115, 1116, 1117, 5-HT2C antagonists, 118, 120 1118 5-HT2C ligands, 120 Genetics, 1096, 1097, 1098, 1114,

5-HT6 ligands, 122, 123 1115, 1158, 1159, 1161, 1164, 1167, 1168, 1171, 1174, 1175 5-HT7 ligands, 120, 121 Neurobiology, 1155, 1156 644784, 580, 582 Neurochemistry, 1156 A-77000, 1067 Dopamine, 1157, 1158, 1161, 1162, Abaperidone, 579, 581 1163, 1164, 1165, 1166, 1167, 1175 ABT-089, 1192, 1193 Noradrenaline, 1168, 1169, 1170, 1171, AC-5216, 251, 1062 1172, 1173 ACP-103, 429, 580, 583 Serotonin, 1173, 1174 ACPC, 250, 253 SNAP-25, 1175, 1176 ACR-16, 579, 582 Pathophysiology, 1118 Adatanserin, 1059 Electrophysiology, 1121 ADD, 1091, 1130, See ADHD Executive functions, 1118 ADHD, 176, 181, 392, 733, 1091, 1092, Neuroimaging, 1119, 1120 1094, 1095, 1096, 1097, 1098, 1099, Symptoms, 1122, 1123, 1124 1100, 1105, 1106, 1107, 1108, 1110, 1111, 1112, 1113, 1114, 1115, 1116, Treatment, 1133 1117, 1118, 1119, 1120, 1121, 1122, Behavioral theraphy, 1142, 1143 1123, 1124, 1125, 1126, 1127, 1128, Antidepressants, Antipsychotics, Anxiolytics Edited by H. Buschmann, J. L. D´ıas, J. Holenz, A. Párraga, A. Torrens, and J. M. Vela Copyright © 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-31058-6

1198 Index

Multimodal treatment programs, 1144 Face validity, 143, 924 Non-stimulants, 1138, 1139, 1140, Genetic validity, 924 1141, 1142 Predictive validity, 143, 450, 924 Psychostimulants, 1134, 1135, 1136, Reliability, 450, 924 1137, 1176 Animal models of anxiety, 669, 762, 926, Adinazolam, 251, 1066 937 ADX-10059, 1056 Conditioned AFQ-056, 1056 Conflict tests, 935 AFX-221, 1192 Fear potentiated startle, 934 AGN-2979, 1060 Shock-induced freezing, 934 Agomelatine, 129, 252, 261 Shock-induced ultrasonic vocalizations, Agoraphobia, 620, 621, 624, 646, 807, 881, 936 884, 888 Shock-probe burying, 935 Ainazolam, 260 Drug abuse, 693 Alnespirone, 250, 255, 1060 Implication for drug discovery, 940 Alprazolam, 77, 89, 951, 953 Unconditioned Synthesis, 951, 952, 953 Elevated plus maze, 930 Use, PK and Metabolism, 953 Hole board, 932 Amantadine, 98 Light/dark transitions, 929 Amarin, 130, 249, 251 Mouse defense test battery, 933 Amibegron, 1068 Novelty-supressed feeding task, 933 Amineptine, 79, 192, 193 Open field paradigm, 928 Synthesis, 193 Social interaction, 931 Use, PK and Metabolism, 193 Zero plus maze, 930 Aminoglutetimide, 97 Animal models of depression, 145 Amisulpride, 377, 403, 423, 491, 493, 577, Chronic mild stress, 148 578 Chronic severe stress, 148 Synthesis, 577 Conditioned place preference, 156 Use, PK and Metabolism, 578 Forced swimming test, 151 Amitriptyline, 74, 75, 79, 113, 174, 181, 185 Genetic models, 158 Synthesis, 174 Intracraneal self-stimulation, 154 Use, PK and Metabolism, 174 Learned heplessness, 146 Amoxapine, 79, 190, 191 Olfactory bulbectomy, 145 Synthesis, 190 Social loss and deprivation, 156 Use, PK and Metabolism, 190 Sucrose preference, 155 Ampakine, 251 Tail suspension test, 152 Animal models Water despair, 151 Construct validity, 144, 450, 924 Withdrawal from psychostimulants, 150 Ecological validity, 924 Etiological validity, 924

Index 1199

Animal models of schizophrenia, 450 Glutamatergic neurotransmission, 425 Complexity, 449, 450 Muscarinic/nicotinic receptors, 428

Genetic models, 468 NK3 antagonists, 427 Dopaminergic system, 471 Non-pharmacological treatment, 377 Glutamatergic system, 470 NTS1 antagonists, 428 Others, 472 Rapid dissociation, 422

Neurodevelopmental models, 464 Role of D2 partial agonism, 424 Disruption of neurogenesis, 467 Anxiety Neonatal hippocampal lesion, 465 Agoraphobia, 620, 624, 646 Perinatal infection, 468 Anatomy of obsessive–compulsive disorder, 726, 732 Perinatal malnutrition, 468 Benzodiazepines in posttraumatic stress Pharmacological models, 453 disorder, 714 Dopaminergic agonists, 459 Biochemistry of obsessive–compulsive NMDA/glutamate antagonists, 453 disorder, 725 Serotonergic agents, 461 Catecholamines in posttraumatic stress disorder, 710 ANPH-102, 1063 Childhood anxiety, 637, 657 Anticonvulsivants, 97 Cholecystokinin and memory, 850 Antidepressants, 22, 68, 73, 87, 88, 129, 906, 909, 1006, 1138, 1189 Cholecystokinin in panic disorder, 723 Basic aspects, 69, 111 Classification, 619, 881 Diversity, 73, 112 Cognition in childhood anxiety, 776 Efficacy, 71 Diagnosis Information to the patient, 70 Generalized anxiety disorder, 887 Interactions, 76 Obsessive–compulsive disorder, 891 Maintenance therapy, 71 Panic disorder, 884 Mecanism of action, 68 Social phobia, 889 Response-predicting factors, 93 Specific phobia, 890 Side-effects, 74 Drug abuse and animal models, 693 Treatment combination, 99 Drug abuse and anxiety, 685 Treatment optimization, 95 Generalized anxiety disorder, 692 Treatment potentiation, 95 Genetics, 696 Treatment switching, 99 Neurobehavioral mechanisms, 697 Treatment-resistant, 94 Obsessive–compulsive disorder, 691 Withdrawal, 72 Panic disorder, 685 Antipsychotics, 375, 389 Personality traits, 695 Basic aspects, 375, 389 Posttraumatic stress disorder, 687

CB1 antagonists, 428 Social phobia, 689

D2/D3 only hypothesis, 423 Early stress in childhood anxiety, 769

D4 antagonists, 427

1200 Index

Electroencephalography in generalized Maltreatment in childhood anxiety, 769 anxiety disorders, 783 Memory bias, 808 Epidemiology, 645 Memory bias in generalized anxiety Agoraphobia, 646 disorder, 817 Childhood anxiety, 657 Memory bias in obsessive–compulsive disorder, 814 Generalized anxiety disorder, 651, 886 Memory bias in panic disorder, 810 Mixed anxiety–depressive disorder, 655 Memory bias in posttraumatic stress Obsessive–compulsive disorder, 652, disorder, 816 890 Memory bias in social phobia, 812 Panic disorder, 646, 882 Memory disturbances, 819 Posttraumatic stress disorder, 653 Memory processes, 807 Social phobia, 648, 888 Mixed anxiety–depressive disorder, 636, Specific phobia, 650, 889 655 Etiology, 667 Neurobiology of anxiety–depression Environment and genetics, 676 disorder, 784 Generalized anxiety disorder, 886 Neurobiology of childhood anxiety, 761, 762, 767, 768, 769, 775, 776 Genetics, 673, 674, 675 Neurobiology of generalized anxiety Obsessive–compulsive disorder, 890 disorder, 777 Panic disorder, 883 Neurobiology of generalized anxiety Specific phobia, 890 disorders, 778, 782, 783 Stress, 667 Neurobiology of obsessive–compulsive disorder, 725, 726, 728, 732 Stress and HPA, 668, 669, 671 Neurobiology of panic disorder, 717, 718, GABA-Benzodiazepines in panic disorder, 719, 720, 721, 722, 723 722 Neurobiology of posttraumatic stress GABAergic and cholinergic interactions, disorder, 709, 710, 711, 713, 714, 715 853 Neurobiology of social phobia, 734, 735, Generalized anxiety disorder, 628, 651, 739, 740, 742 692, 885, 886, 887 Neurochemistry of childhood anxiety, 762, Genetics, 673, 674, 696 767, 768 Glutamate and memory, 852 Neurochemistry of generalized anxiety Hippocampal dissociations, 855 disorders, 778 HPA axis in posttraumatic stress disorder, Neurochemistry of panic disorder, 718 711 Neuroendocrinology and neurochemistry Individual differences, 860 of social phobia, 735 Management Neuroimaging in generalized anxiety disorders, 782 Generalized anxiety disorder, 887 Neuroimaging in panic disorder, 723 Obsessive–compulsive disorder, 892 Neuroimaging in posttraumatic stress Panic disorder, 885 disorder, 715 Social phobia, 889 Neuroimaging in social phobia, 739 Specific phobia, 890 Neuronal plasticity, 857

Index 1201

Neuropsychology of obsessive– AP-521, 1060 compulsive disorder, 728 Aripiprazole, 377, 403, 404, 424, 491, 493, Neuropsychology of social phobia, 740 571, 572, 1163 Neuropsysochology of posttraumatic Synthesis, 572 stress disorder, 715 Use, PK and Metabolism, 572 Noradrenaline in panic disorder, 719, 721 Artofisopam, 1064 Obsessive–compulsive disorder, 630, 652, Asenapine, 250, 259, 429, 579, 585 691, 890, 891, 892 Atomoxetine, 1141, 1142, 1183, 1189 Panic attack, 619, 882 Synthesis, 1189, 1190 Panic disorder, 622, 646, 685, 882, 883, 884, 885 Use, PK and Metabolism, 1189 Posttraumatic stress disorder, 633, 653, Attention deficit hyperactivity disorder. See 671, 687 ADHD Prefrontal cortex, 847, 856 Atypical antidepressants, 112, 116 Serotonine in panic disorder, 720, 721 Atypical antipsychotics, 96, 401, 403, 493, 549, 553, 577 Serotonine in posttraumatic stress disorder, 713 5-HT2A/D2 hypothesis, 403

Sex differences, 862 Role of 5-HT1A, 409

Sex differences in childhood anxiety, 775 Role of 5-HT2C, 414

Social costs, 658 Role of 5-HT6/5-HT7, 416

Social phobia, 626, 648, 689, 888, 889 Role of Į1-adrenoceptor, 417

Specific phobia, 625, 650, 889, 890 Role of Į2-adrenoceptor, 420 Stress response, 667, 668, 669, 856, 857, AV-608, 1061 860, 862 AVE-1625, 580, 584 Treatment Azamianserin. See Mirtazapine 5-HT agonists, 900, 904 1A Basolateral amygdala, 843 Antidepressants, 897, 902, 909, 911, 914 Bay-q-7821, 1066, 1067 Befetupitant, 1063 Benzodiazepines, 899, 903, 907, 910, 912 Benperidol, 491, 492, 522 Generalized anxiety disorder, 902, 903, Synthesis, 522 904 Use, PK and Metabolism, 522 Obssesive–compulsive disorder, 914 Benzodiazepines, 88, 896, 900, 904, 917, Overview, 896 933, 934, 936, 951, 961, 1061, 1064 Panic disorder, 908, 909, 910 Adverse events, 89 Posttraumatic stress disorder, 911, 912, Interactions, 90 913 Management, 90 Prevention of posttraumatic symptoms, 913 Overdose, 90 Social phobia, 905, 907 Pharmacokinetics, 89 Specific phobia, 908 Risk of dependence, 90 Working memory, 847 Bifeprunox, 250, 259, 403, 429, 580, 585 Binospirone, 1052

1202 Index

Bipolar disorder, 3, 9 Carbamazepin, 240 Bis(olanzapine), 579, 585 Synthesis, 240 BL-1020, 580, 582 Use, PK and Metabolism, 241 BLA, XXXIII, 835, 836, 837, 839, 840, 841, Carnosine, 580, 584 842, 843, 844, 846, 847, 848, 852, See Carpipramine, 491, 492, 537, 1019, 1020 Basolateral amygdala Synthesis, 537, 1019, 1020 Blonanserin, 579, 586 Use and PK, 1020 BMS-562086, 250, 255 Use, PK and Metabolism, 537 BMY-13805, 1065 Casopitant, 130, 251, 256, 1064 Bretazenil, 1066 Catatonic schizophrenia, 301, 366 BRL-46470, 1058 CCK, 723, 778, 781, 782, 850, 851, 852, See BRL-46470A, 1060 Cholecystokinin Brofaromine, 251, 259 CGP-12103A, 1068 Bromantan, 1062 CGP-361A, 1051 Bromantane, 1062 CGP-608, 1061 Bromazepam, 89, 985, 987 CGS-15040A, 1059 Synthesis, 986, 987, 988 CGS-19480A, 1051 Use, 987 CGS-19755, 1067 Bromocryptine, 98 CGS-20625, 1058 Bromperidol, 491, 492, 541 CGS-8216, 1051 Synthesis, 541 Chlordiazepoxide, 89, 976, 977 Use, PK and Metabolism, 541 Synthesis, 976 Brotizolam, 970, 973 Use, PK and Metabolism, 977 Synthesis, 970, 971, 972 Chlorpromazine, 376, 396, 491, 492, 495, Use and PK, 973 496, 1013, 1015 BTG-1501, 1060 Synthesis, 496 BTG-1640, 1053 Use, PK and Metabolism, 496 Bupropion, 242, 243, 1139 Chlorprothixene, 397, 491 Synthesis, 242 Cholecystokinin, 723, 850 Use, PK and Metabolism, 243 CI-1043, 1068 Buspirone, 98, 900, 904, 917, 1002, 1003 CI-988, 723, 782, 1060 Synthesis, 1002 Cianopramine, 258 Use, PK and Metabolism, 1003 Cipralisant, 1192, 1193 Butriptyline, 180 Citalopram, 74, 75, 114, 200, 201, 202 Synthesis, 180 Synthesis, 200 Use, 180 Use, PK and Metabolism, 201 CAM-958, 1060 CL-216303, 1064 Cannabidiol, 580, 584 Classic antipsychotics, 498, See Typical antipsychotics

Index 1203

Clobazam, 89, 988 Cyamemazine, 491, 492, 532, 534, 1020 Metabolism, 988, 990 Synthesis, 532, 1021 Synthesis, 988, 989 Use, 532 Clomipramine, 74, 75, 113, 184, 185, 186, Cyclobenzaprine, 1044 917, 1043 Synthesis, 1045, 1046, 1047 Synthesis, 184, 1043, 1044 D-13112, 1066 Use, PK and Metabolism, 185 Delucemine, 130, 251, 254 Clonazepam, 907, 954 Depression Synthesis, 954, 955 Biochemistry, 63 Clorazepate, 995 Classification, 52 Synthesis, 995, 996 Cronobiological hypothesis, 27 Use, PK and Metabolism, 995 Epidemiology, 61 Clorazepate, 995 Etiology, 7, 10 Clorgyline, 259 Genetics, 10 Clotiazepam, 996, 998 Infectious hypothesis, 28 Synthesis, 996, 997 Introduction, 3, 51 Use and PK, 998 Management, 90 Clotiazepam, 996 Monoamine hypothesis, 14, 64 Clovoxamine, 251, 260 Neuroendocrine hypothesis, 23, 66 Clozapine, 377, 402, 403, 404, 417, 422, Neuroendocrinology, 66 491, 493, 549, 550, 1162 Neuroimaging, 29 Synthesis, 550 Neuropathology, 309 Use, PK and Metabolism, 550 Neurophysiology, 29 CP-122721, 251, 256 Neuroplasticity, 31 CP-143867, 1053 Non-pharmacological treatment, 100 CP-316311, 250, 255 Pathogenesis, 14 CP-409092, 1053 Physiopathology, 63 CP-93393, 1068 Prevalence, 6 CP-93393-1, 1068 Sleep, 27 CR-2945, 1054 Desipramine, 77, 79, 113, 176, 181 CRD-101, 581, 582 Synthesis, 181 CRF, XXXII, XLV, 23, 24, 26, 27, 67, 123, 124, 668, 669, 670, 672, 698, 699, 700, Use, PK and Metabolism, 181 713, 737, 762, 763, 764, 766, 767, 768, Destroamphetamine, 1183 778, 782 Desvenlafaxine, 252, 261, 1069 CRF Antagonists, 123 Dextofisopam, 1064 CX-516, 251, 257, 426 Dextroamphetamine, 97, 1136, 1183, 1184 CX-717, 1192, 1194 Synthesis, 1183

Use and PK, 1184

1204 Index

Diazepam, 77, 89, 954, 956, 959, 961 Dysthymic disorder, 3, 8 Metabolism, 961 Classification, 60 Synthesis, 956, 957, 959, 960 Combined treatment, 103 Use and PK, 961 Epidemiology, 63 Dibenzepine, 248 Introduction, 8 Dihydroepiandrosterone, 97 Pharmacological treatment, 101, 102 Dilopetine, 1062 Psychosocial treatment, 103 Dimetacrine, 248 E-4424, 1059 Divalproex, 243 E-6006, 251, 253, 1062 Synthesis, 243 E-6039, 251, 253, 1062 Use PK and Metabolism, 244 Ebaltozan, 1053 Divaplon, 1058 EGIS-5810, 1058 DMP-904, 250, 253 EGIS-6775, 1051 DMXB-Anabaseine, 580, 584 Eglumegad, 1061 DN-2327, 1067 ELB-139, 1062 dopamine reuptake inhibition, 119 Electroconvulsive therapy, 100 Dosulepin, 183 Elzasonan, 130, 250, 255 Synthesis, 183 Emapunil, 251, 257, 1062 Use, PK and Metabolism, 183 EMD-56551, 1053 DOV-102677, 249, 252, 1193 EN-01, 1062 DOV-216303, 249, 255, 1064 Enciprazine, 1066 DOV-21947, 249, 252 Endixaprine, 1057 Doxepin, 113, 187 Eplivanserin, 1059, 1060 Synthesis, 187 Eptapirone, 1062 Use, PK and Metabolism, 188 Escitalopram, 114, 200, See Citalopram DP-VPA, 251, 256 Eslicarbazepine, 251, 260 Droperidol, 491, 492, 517, 518 Ethyl loflazepate, 974, 976 Synthesis, 518 Synthesis, 974, 975 Use and PK, 518 Use, 976 Droperidole, 397 Etifoxine, 1010, 1011 DU-125530, 250, 254 Synthesis, 1010 DU-13811, 260 Use, 1011 DU-29373, 1067 Etizolam, 973 Duloxetine, 74, 86, 225, 226, 228 Synthesis, 973 Synthesis, 225 Use and PK, 973 Use, PK and Metabolism, 226 Etoperidone, 216 DVS-233, 129, 1069 Synthesis, 216 Use, 216

Index 1205

F-11440, 1062 GR, 23, 26, 124, 130, 669, 764, 765, 766, 835, 836, 838, 840, 845, 846, 847, 848, F-2692, 1052 See Glucocorticoid receptor Farampator, 251, 257, 580, 583 GSK-372475, 250, 255, 1193 FCE-23884, 1057 guanfacine, 1138, 1140, 1170, 1194 Fenobam, 1065 GV-150013, 1060 FG-10571, 1052 GW-150013, 1060 Flesinoxan, 1067 GW-273293, 251, 257 Fluoxetine, 74, 75, 77, 114, 194, 195, 197, GW-597599, 1063 1189 GW-679769, 1064 Synthesis, 194 GW-823296, 251, 253, 1056 Use, PK and Metabolism, 197 GW-876008, 250, 253, 1056 Flupentixol, 376, 397, 491, 492, 523, 524, 525 GYKI-51189, 1058 Synthesis, 524 GYKI-52322, 1051 Use, PK and Metabolism, 524 Halazepam, 993, 995 Fluphenazine, 376, 396, 403, 491, 492, 509, Synthesis, 993, 994 510, 1014, 1015 Use, 995 Synthesis, 509, 1014, 1015 Haloperidol, 77, 376, 397, 403, 404, 414, Use, PK and Metabolism, 510 491, 492, 511, 512, 513, 515 Fluspirilene, 491, 492, 530, 531 Synthesis, 512 Synthesis, 531 Use, PK and Metabolism, 513 Use, 531 Harmala, 114 Fluvoxamine, 74, 75, 77, 114, 202, 203 Hebephrenic schizophrenia, 301, 366 Synthesis, 202 HPA, XXXV, XXXVI, XLV, 23, 24, 25, 26, 27, 33, 123, 124, 149, 157, 159, 668, 670, Use, PK and Metabolism, 203 671, 672, 677, 685, 698, 699, 709, 711, Folate, 98 712, 716, 735, 763, 767, 774, 778, 779, 782, 784, 854, 860, 862, 883, See GAD, 651, 652, 659, 673, 676, 692, 693, Hypothalamic–pituitary–adrenal axis 721, 738, 777, 778, 779, 780, 781, 782, 783, 784, 807, 817, 881, 883, 885, 886, Hydroxyzine, 1041, 1042 887, 888, 889, 902, 903, 904, 905, 910, Synthesis, 1041, 1042 917, 926, 1029, 1032, 1038, See Generalized anxiety disorder Use and PK, 1042 Gedocarnil, 1052 Hypothalamic–pituitary–adrenal axis, XXXVI, 23, 67, 123, 668, 671, 711 Gepirone, 129, 250, 259, 1065 ICI-118551, 1065 Gidazepam, 1061 ICI-170809, 1058 Girisopam, 1058 Ifoxetine, 249, 254 Glemanserin, 1052 Iloperidone, 579, 585 Glucocorticoid receptor, 835 Imipramine, 74, 75, 77, 79, 113, 175, 176, Glucocorticoids, XXXV, 124, 838 917 Glutamatergic targets, 128 Synthesis, 176 GPE, 251, 258 Use, PK and Metabolism, 176

1206 Index

Inositol, 98, 917 Lithium, 32, 94, 96, 112, 115, 239, 491, 492, 494 IP-456, 1068 Use and PK and Metabolism, 239 Ipsapirone, 1066, 1067 Use, PK and Metabolism, 494 Irindalone, 1057, 1059 lobeline, 1192 Isamoltan, 1051 Lobeline, 1193 Isocarboxazid, 114, 235 Lofepramine, 74, 113, 192 Synthesis, 235 Synthesis, 192 Use, PK and Metabolism, 235 Use, PK and Metabolism, 192 Isovaleramide, 254 Lonasen, 429 Itriglumide, 1054 Lorazepam, 89, 963, 964, 965 JNJ-19567470, 131, 250, 253, 1056 Synthesis, 963, 964 Kava extract, 1050 Use, PK and Metabolism, 964 KC-9172, 1051 Lormetazepam, 89, 964, 965 Ketazolam, 89, 991, 993 Synthesis, 965 Synthesis, 992 Use, PK and Metabolism, 965 Use, 993 Loxapine, 491, 492, 534, 535 Ketoconazole, 77, 97 Synthesis, 534 L-0068, 1062 Use, PK and Metabolism, 535 L-365260, 1058 LU-21-098, 1059 Ladasten, 1062 LU-21-098X, 1057 Lamotrigine, 246, 247, 580, 581, 586 LU-28-179 HCl, 1056 Synthesis, 247 Lu-31-130, 580, 582 Use, PK and Metabolism, 247 Lu-AA-21004, 249, 252 LAX-101, 130, 257 Lu-AA-24530, 251, 254 LAX-201, 249, 255 Lu-AA34893, 1056 Laxdale, 249 Lurasidone, 579, 582 Lesopitron, 1059 LY-2140023, 580, 584 Levomepromazine, 376, 491, 492, 502 LY-277359, 1068 Synthesis, 502 LY-314582, 1061 Use, PK and Metabolism, 502 LY-354740, 1061 Levoprotiline, 1068 LY-404039, 580, 584 Levosulpiride, 491, 492, 526, 527, 542, 543 LY-544344, 1055 Synthesis, 542 MADD, 784, 785, See Mixed anxiety– Use, PK and Metabolism, 543 depression disorder Levotofisopam, 998, 1055 Major depressive disorder, 57, 85, See Licarbazepine, 251, 259 Depression Lisdexamphetamin, 1194 Manic depressive disorder. See Bipolar disorder Lisdexamphetamine, 1192

Index 1207

MAOIs, 22, 81, 82, 83, 84, 88, 92, 94, 100, Steps, 805 102, 111, 112, 113, 118, 131, 233, 237, Storage, 832 889, 897, 915, 1189, See Monoamine oxidase inhibitors Temporal nature, 805 Maprotiline, 74, 79, 189 Meprobamate, 1039, 1040 Synthesis, 189 Synthesis, 1040 Use, PK and Metabolism, 190 Use, PK and Metabolism, 1040 MCH antagonists, 126 metanicotine, 1192 MCI-242, 1065 Metanicotine, 1193 MDL-11939, 1052 Metapramine, 248 MDL-73005EF, 1052 Methamphetamine, 1184, 1185 ME-3127, 1062 Synthesis, 1184 Mebicar, 1039 Use, 1185 Synthesis, 1039 Methamphetamine, 1184 Mecamylamine, 1192 Methylphenidate, 1134, 1136, 1185, 1187 Medazepam, 954, 980, 982 Synthesis, 1185 Synthesis, 980, 981, 982 Use, PK and Metabolism, 1187 Use and PK, 982 Methylphenidate, 1185 Medetomidine, 1057 Metirapone, 97 Medifoxamine, 251, 254 Mianserin, 74, 75, 79, 87, 229, 248 Melitracen, 248 Midazolam, 89, 965, 968 Melperone, 491, 1016 Metabolism, 968 Synthesis, 1016 Synthesis, 966, 967 Use, PK and Metabolism, 1016 Use and PK, 968 MEM-1003, 251, 257 Mifepristone, 581, 586, 1026, 1027 MEM-3454, 580, 582 Synthesis, 1027 Memory Milnacipran, 220, 221 Categories, 804 Synthesis, 220 Cholecystokinin, 850 Use and Metabolism, 221 Consolidation and emotions, 834 Miraxion, 130, 251, 257 Glutamate, 852 Mirisetron, 1053 Hippocampal dissociations, 855 Mirtazapine, 74, 87, 229, 230 Neurobiology, 831 Synthesis, 230 Processes and mechanisms, 803 Use, 230 Release of stress hormones, 837, 845, Mixed amphetamine salts, 1136, 1183 847 MJ-13805, 1065 Relevance of Hippocampus, 855, 857 MKC-242, 411, 1065 Relevance of the amygdala, 835, 836, MN-305, 1065 837, 843, 847

Retrieval, 845

1208 Index

Moclobemide, 74, 75, 114, 237, 238, 898, NK1 antagonists, 125 999, 1000 NKP-608, 1061 Synthesis, 237, 999, 1001 Noradrenaline and specific serotonergic Use, PK and Metabolism, 237 antidepressants, 229 Modafinil, 580, 585, 1140, 1192 Noradrenaline reuptake inhibitors, XL, 87, 112, 114, 231 Monoamine oxidase inhibitors, XL, 81, 112, 113, 114, 116, 233, 999 Norclozapine, 584 Adverse effects, 83 norclozapine/N-desmethylclozapine, 580 Indications, 83 Nordazepam, 990, 991, 993 Interactions, 82 Synthesis, 991 Intoxication, 83 Use, PK and Metabolism, 991 Mecanism of action, 82 Nortriptyline, 113, 182 Non-selective, 233 Synthesis, 182 Pharmacokinetics, 82 Use, PK and Metabolism, 182 Precautions, 82 NPS-1776, 251, 254 Type A, 237 NRP-104, 1192, 1194 Mosapramine, 491, 492, 545, 546 NS-2359, 255, 1193 Synthesis, 545 NS-2710, 1062 Use, PK and Metabolism, 546 Ocaperidone, 579, 582 MPV-785, 1057 OCD, 194, 210, 652, 653, 655, 673, 691, 692, 725, 726, 727, 728, 729, 730, 731, NAE-086, 1053 732, 733, 734, 735, 737, 740, 741, 807, NBI-34041, 26, 1055 814, 820, 881, 890, 891, 892, 914, 915, 916, 917, See Obsessive–compulsive ND-7001, 251, 253, 1056 disorder Neboglamine, 250, 253, 580, 582 O-Desmethylvenlafaxine, 1069 Nefazodone, 77, 217, 218 Olanzapine, 377, 403, 404, 430, 491, 493, Synthesis, 217 559, 560, 563 Use, PK and Metabolism, 218 Synthesis, 559 Nemifitide, 130, 251, 258 Use, PK and Metabolism, 560 Nemonapride, 491, 492, 547, 548 Omega-3 fatty acids, 99 Synthesis, 547 Ondansetron, 580, 583 Use, 548 ONO-2333MS, 26, 250, 253, 1056 NEO-339, 1192 OPC-14523, 130, 254 Nerisopam, 1051 Opipramol, 179 Neurotrophins, 126 Synthesis, 179 NGD-91-1, 1053 Use, 179 NGD-91-2, 1056 ORG 24448, 429 NGD-91-3, 1062 ORG 5222, 429 NGI-101, 1064 ORG-25935, 580, 581 NGI-221, 1192 ORG-33062, 1065

Index 1209

ORG-34517, 251, 257 Phenelzine, 74, 75, 114, 234, 917 Osemozotan, 1065 Synthesis, 234 Oxaprotiline, 250, 259 Use, PK and Metabolism, 234 Oxazepam, 89, 978, 979 Phosphodiesterase inhibitors, 128 Synthesis, 978, 979 Photostimulation, 100 Use and PK, 979 Piberaline, 251, 257 Oxprenolol, 1024, 1026 Pikamilone, 1059 Synthesis, 1024, 1025 Pimozide, 376, 397, 491, 492, 528, 529 Use, PK and Metabolism, 1026 Synthesis, 529 Oxycodeine, 98 Use, PK and Metabolism, 529 Oxymorphine, 98 Pindolol, 98 Pagoclone, 1068 Pipotiazine, 491, 492, 533, 534 Paliperidone, 579, 585, 586 Synthesis, 533 Panadiplon, 1052 Use, PK and Metabolism, 534 Paranoid schizophrenia, 301, 367 Piricapiron, 1061 Paroxetine, 74, 75, 77, 114, 206, 208, 1190 Pramipexol, 98 Synthesis, 206 Pramipexole, 250, 255 Use, PK and Metabolism, 208 Prazepam, 983 Pazinaclone, 1067 Synthesis, 983, 984 PD, 721, See Panic disorder Prefrontal cortex, 843 PD-134308, 1060 Pregabalin, 1032, 1038 PD-216948, 1055 Synthesis, 1033, 1034, 1035, 1036, 1037 Pemoline, 1166, 1183 Use, 1038 Periciazine, 491, 492, 519, 520 Procaine, 252, 261 Synthesis, 519 Prochlorperazine, 397, 491, 492, 499, 500 Use, 520 Synthesis, 500 Perospirone, 491, 493, 570 Use, PK and Metabolism, 500 Synthesis, 570 Promazine, 491, 492, 501 Use, PK and Metabolism, 570 Synthesis, 501 Perphenazine, 376, 397, 491, 492, 503, 504 Use and PK, 501 Synthesis, 504 Propranolol, 77, 1021, 1023 Use, PK and Metabolism, 504 Synthesis, 1021, 1022, 1023 PF-00184562, 580, 582 Use, PK and Metabolism, 1023 PFC, 15, 29, 30, 305, 310, 312, 313, 314, Protriptyline, 113, 186, 187 315, 318, 320, 321, 324, 325, 389, 411, Synthesis, 186 415, 417, 420, 421, 426, 430, 449, 453, 455, 457, 458, 461, 462, 464, 465, 466, Use, PK and Metabolism, 186 467, 729, 835, 843, 847, 848, 849, 850, PRX-00023, 129, 250, 258, 1068, 1192, 852, 856, See Prefrontal cortex 1194 PH-94B, 1063 Psychosocial treatments, 101, 377, 1142

1210 Index

Psychostimulants, 97, 1134, 1166, 1183 Risperidone, 77, 377, 403, 404, 491, 493, 555, 556, 557 Psychosurgery, 101 Synthesis, 556 PTSD, 210, 653, 654, 655, 659, 668, 671, 687, 688, 689, 709, 710, 711, 712, 713, Use, PK and Metabolism, 557 714, 715, 716, 717, 736, 738, 761, 767, Ritanserin, 408, 1066 768, 769, 770, 771, 772, 774, 807, 816, 817, 819, 820, 881, 885, 892, 911, 912, Ro-16-6028, 1066 913, 917, See Panic disorder Ro-16-6028/000, 1066 PW-4112, 251, 260 Ro-46-2153, 1054 PW-4123, 581, 582 Ro-48-6791, 1054 Quetiapine, 261, 377, 403, 404, 491, 493, Ro-48-8684, 1054 564, 565 Ro-67-5930, 1063 Synthesis, 564 Rolipram, 251 Use, PK and Metabolism, 565 Romergoline, 1057 Quinupramine, 248 RP-31264, 1065 R-1204, 1055 RP-59037, 1068 R-1678, 581, 582 RP-62955, 1068 R-228060, 257 Ru-32698, 1058 R-55667, 1066 RWJ-51204, 1062 R-56413, 1057 S)-DMZ, 1055 R-673, 1064 S-15535, 1053 Radafaxine, 130, 250, 255 S-16924, 1061 Reboxetine, 74, 87, 231, 232 S-20098, 261 Synthesis, 231 S-20499, 1060 Use, PK and Metabolism, 232 SA-4503, 251, 256 Remoxipride, 403, 491, 492, 544 S-adenosyl-methionine, 98 Synthesis, 544 Sapropterin, 1011 Use, PK and Metabolism, 544 Synthesis, 1011, 1012 Repetitive transcranial magnetic stimulation, 100 Saredutant, 129, 251, 260, 1068 Residual schizophrenia, 301, 367 Saripidem, 1059 RG-2417, 1064 SAX-187, 1056 RGH-188, 250, 252, 580, 583 SB-163090, 250, 252 Ricasetron, 1058, 1060 SB-243213, 1054 Rilmazafone, 1006, 1007 SB-247853, 250, 252, 1054 Metabolism, 1007, 1008 SB-723620, 1055 Synthesis, 1006, 1007 SB-773812, 580, 583 Use and PK, 1007 SC-48274, 1060

Index 1211

Schizophrenia Selanc, 1065 Affective symptoms, 358 Selective serotonin reuptake inhibitors, XLIV, 84, 112, 114, 193, 198, 917 Attention deficit, 351 Adverse events, 85 Brain pathology, 308 Indications, 85 Cellular abnormalities, 313 Management, 84 Classification, 300 Pharmacokinetics, 84 Cognitive deficit, 305, 347, 350, 356 Serotoninergic syndrome, 85 Course, 307 Selegiline, 114, 252, 261 Diagnosis, 300 Selfotel, 1067 Dopaminergic hypothesis, 318, 369, 391 SEP-174559, 1055 Epidemiology, 306, 341, 360 SEP-225289, 130, 250, 252 Etiology, 367 Serazapine, 1059 Executive function, 354 Serotonin and noradrenaline reuptake GABAergic hypothesis, 325 inhibitors, XLIV, 86, 112, 115, 220 Genetics, 368 Adverse events, 86 Glutamatergic hypothesis, 321, 370 Indications, 86 Infectious hypothesis, 372 Sertindole, 377, 403, 491, 493, 573, 574 Introduction, 299, 335, 336 Synthesis, 573 Language disorders, 355 Use, PK and Metabolism, 574 Memory alterations, 352 Sertraline, 74, 75, 77, 114, 210, 211 Negative symptoms, 345 Synthesis, 210 Neuroendocrine hypothesis, 372 Use, PK and Metabolism, 211 Neuroimaging, 309, 371 Setiptiline, 248 Neurophysiology, 371, 391, 450 SGS-518, 580, 583 Onset, 365 SGS-742, 1192, 1193 Pathogenesis, 316 SH-530, 1052 Positive symptoms, 342 Simple schizophrenia, 301, 367 Prognosis, 373 Siramesine, 1056 Psychosocial factors, 372 SL-65.1498, 1063 Risk factors, 361 SL-651498, 1063 Semiology, 341 SL-85.0274, 1059 Serotoninergic hypothesis, 320, 370 Sleep deprivation, 27, 100 States, 366 SLV-308, 259 Suicide risk, 360, 363, 364 SLV-313, 583 SEB-324, 1059 SLV-314, 249, 252, 580, 581 SEC-579, 1053 SNRIs, 22, 86, 112, 115, 118, 131, 146, 220, Secretin, 429 See Serotonin and noradrenaline reuptake inhibitors Seganserin, 1057

1212 Index

SP, 125, 734, 735, 736, 737, 738, 739, 740, Tandospirone, 249, 491, 492, 548, 1003, 741, 742, 743, See Social phobia 1006 SPD-465, 1192, 1194 Synthesis, 548, 1003, 1004, 1005 SPD-503, 1192, 1194 Use, 548, 1006 SPPI-339, 1192 TC-5231, 1192 SR-149415, 1063 TCAs, 22, 78, 79, 80, 83, 84, 85, 99, 100, 111, 112, 113, 115, 124, 129, 131, 147, SR-41378, 1057 149, 151, 159, 173, 176, 178, 181, 182, SR-46349B, 1060 185, 186, 188, 190, 192, 193, 194, 197, 201, 203, 208, 211, 215, 216, 218, 220, SR-46349C, 1059 231, 233, 234, 239, 243, 245, 248, 508, SR-48965, 1068 579, 897, 898, 899, 903, 909, 910, 912, 1183, 1184, See Tricyclic antidepressants SR-48968, 1068 Teniloxazine, 251, 260 SR-489686, 1068 Tetrabamate, 1009 SR-58611, 251, 260, 1068 Synthesis, 1009, 1010 SR-58611A, 1068 Thioridazine, 397, 491, 492, 506, 507 SSR-125543, 250, 253, 1055 Synthesis, 506 SSR-125543A, 26, 1055 Use, PK and Metabolism, 506 SSR-149415, 251, 256, 1063 Thiothixene, 397, 491, 492, 520, 522 SSR-240600, 1063 Synthesis, 520 SSR-240600C, 1063 Use, PK and Metabolism, 520 SSR-411298, 1055 Tiagabine, 1029, 1031 SSR-504734, 580, 581 Synthesis, 1030, 1031 SSRIs, 11, 19, 22, 83, 84, 85, 92, 99, 102, 111, 112, 114, 115, 117, 118, 119, 120, Use, PK and Metabolism, 1031 126, 129, 131, 149, 151, 152, 173, 194, Tianeptine, 248, 1017, 1018 195, 233, 249, 430, 508, 677, 713, 714, 720, 736, 883, 889, 892, 897, 898, 899, Synthesis, 1017, 1018 902, 903, 906, 907, 908, 909, 910, 911, Use, PK and Metabolism, 1018 912, 914, 915, 917, 933, 1139, See Selective serotonin reuptake inhibitors Tiapride, 491, 492, 538, 539 St. John’s Wort extract, 122, 251, 260 Synthesis, 538 Sulpiride, 403, 423, 491, 492, 526, 527 Use, PK and Metabolism, 539 Synthesis, 527 Tofizopam, 998 Use, PK and Metabolism, 527 Synthesis, 998, 999 Sultopride, 491, 492, 536, 537 Use, 998 Synthesis, 536 Tolcapone, 429 Use and PK, 537 Toloxatone, 238 Sunepitron, 1068 Synthesis, 238 Suriclone, 1065 Use, PK and Metabolism, 238 SX-5216, 1062 TP-7, 1065 Talaglumetad, 1055 TPA-023, 1054 Talnetant, 429, 580, 583

Index 1213

Tranylcypromine, 74, 82, 114, 236 Vabicaserin, 580, 583 Synthesis, 236 Vagus nerve stimulation, 100 Use, PK and Metabolism, 236 Valnoctamide, 1047, 1050 Trazodone, 75, 88, 114, 214, 215 Synthesis, 1047, 1048, 1049 Synthesis, 214 Use and PK, 1050 Use, PK and Metabolism, 214 Valproic acid, 244, See Divalproex Tricyclic antidepressants, 78, 112, 173, Vasopressin receptor antagonists, 124 915, 1138 VEC-162, 251, 257 Adverse events, 80 Venlafaxine, 74, 77, 86, 223, 224, 917 Indications, 80 Synthesis, 223 Intoxication, 81 Use, PK and Metabolism, 224 Mecanism of action, 78 Veralipride, 491, 492, 540 Pharmacokinetics, 79 Synthesis, 540 Precautions, 79 Use and PK, 540 Prescription, 80 Vesipitant, 251 Trifluoperazine, 397, 491, 492, 508, 509, Vestipitant, 130, 251, 256, 1063 1012, 1013 Vilazodone, 250, 258 Synthesis, 508, 1012 Viloxazine, 245 Use and PK, 509, 1013 Synthesis, 245 Triflupromazine, 491, 492, 505 Use, PK and Metabolism, 245 Synthesis, 505 Viqualine, 249, 258 Use, PK and Metabolism, 505 Virucort, 252, 261 Triiodothyronine, 96 VPI-013, 130, 250, 255 Trimipramine, 113, 178 WAY-100289, 1053 Synthesis, 178 WAY-100579, 1053 Use and PK, 178 WAY-181187, 1056 Tryptophan, 19, 97 WAY-SEB-324, 1059 TS-041, 26, 131, 1056 WAY-SEC-579, 1053 TVX-Q-7821, 1066, 1067 WY-45233, 1069 Typical antipsychotics, 98, 396, 403, 492, 494 Wy-47846, 1058 Dopamine receptors, 398 Wy-48624, 1066 Side-effects, 400 Wy-50324, 1059 U-41123, 1066 XBD-173, 1064 U-78875, 1052 XY-2401, 580, 582 U-93385, 1053 Y-22990, 1052 Umespirone, 1051 Y-23684, 1067 Unipolar depressive disorder. See YKP-10A, 130, 251, 257 Depression YKP-1358, 579, 581 Uridine, 251, 254, 1064

1214 Index

YKP-581, 251, 254 ZM-170809, 1058 Zalospirone, 1058 Zotepine, 491, 493, 553, 555 Zatosetron, 1068 Synthesis, 554 Ziprasidone, 377, 403, 404, 491, 493, 566, Use, PK and Metabolism, 555 567, 570 Zuclopenthixol, 491, 492, 516 Synthesis, 566 Synthesis, 516 Use, PK and Metabolism, 566 Use, PK and Metabolism, 516 ZK-91296, 1057 Į2 antagonists, 118 ZK-93423, 1051